Professor Hugh Sampson joins Scientific Advisory Board of DBV Technologies

The appointment of Key Opinion Leader (KOL) in Allergy and Immunology is of strategic importance to DBV

BAGNEUX, France, May 31, 2012 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the appointment of Pr. Hugh Sampson to its world-class Scientific Advisory Board. In joining the Scientific Advisory Board, Pr. Sampson will provide DBV Technologies with access to his unique expertise in food allergy. Pr. Sampson’s appointment is of strategic importance to DBV Technologies, as the Company works towards the completion of ongoing clinical studies as well as the initiation of several additional clinical studies in peanut and milk allergies.

Hugh A. Sampson, M.D., is a professor of Pediatrics and Immunobiology at the Mount Sinai School of Medicine, N.Y., USA. He is Chief of the Division of Allergy & Immunology in the Department of Pediatrics; Director of the Jaffe Food Allergy Institute; and Dean of Translational Biomedical Science at The Mount Sinai Medical Center. He received his M.D. from the Buffalo State University of New York School of Medicine. Dr. Sampson’s research interests have focused on food allergic disorders, including work on the immuno-pathogenic role of food hypersensitivity in atopic dermatitis, the pathogenesis of food-induced anaphylaxis, the characterization of food-induced gastrointestinal hypersensitivities, the characterization of food allergens, and novel immunotherapeutic strategies (recombinant engineered protein, plasmid DNA, peptide, etc.) for treating food allergies. His research has been funded by a number of grants from the National Institutes of Health (NIH) and private foundations (Clarissa Sosin Foundation and Food Allergy Initiative). He is the Principal Investigator of the NIH-sponsored Consortium of Food Allergy Research (COFAR). Dr. Sampson supervises one clinic/week in pediatric allergy. He is also former President of the American Academy of Allergy Asthma and Immunology (AAAAI) and is the coordinator of DBV Technologies’ phase IIb VIPES study.

Pierre-Henri Benhamou, M.D., Chairman and CEO of DBV, said: “With this crucial addition to its SAB announced today, DBV Technologies further improves its governance. We are thankful to Pr. Hugh Sampson, who decided to join our SAB, thereby validating the importance of our work in the treatment of food allergy. With the reinforcement of our management team and our recent IPO, DBV Technologies now has the key building blocks in place to accelerate its development, opening up a decisive new approach to the treatment of allergy – a major public health issue that is, unfortunately, constantly growing in prevalence.”

About DBV Technologies:

DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient’s tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company’s significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product’s clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The developmental clinical program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy – a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com.

CAUTION: Viaskin® is not approved for sale in the USA.
Contacts

**David Schilansky**
Chief Financial Officer  
DBV Technologies  
Tél. : +33(0)1 55 42 78 75  
david.schilansky@dbv-technologies.com

**NewCap.**  
Financial Communication and investor relations  
Emmanuel Huynh / Alexandra Schiltz  
Tél. : +33(0)1 44 71 94 94  
dbv@newcap.fr

**Ronald Trahan, APR**  
Press relations  
Ronald Trahan  
Tél. : +1 508 359 4005  
rc trähan@ ronaldtrah an.com